Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

HHS' 2018 Greatest Hits: Azar Touts Record FDA Generic Approvals, Drug Pricing And Opioid Actions

Feb 24 2019

• By Brenda Sandburg

HHS Building_1200

Related Content

Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA

Nov 02 2018

Keeping Track: A Diverse Array Of Approvals, A CRL For Evolus' Botox Competitor, And Coherus Refiles Neulasta Biosimilar

May 20 2018

Invitation Accepted: Biopharma Leaders Will Testify At Senate Hearing On Pricing

Feb 08 2019

Senate Drug Pricing Hearing Looms As Unparalleled Event For Pharma

Feb 22 2019

Trulicity DTC Ads Reference Lilly Website For List Price, Cost Sharing Info

Jan 11 2019

Insulin Makers May Be First In Crosshairs Of DeGette Rx Pricing Investigation

Jan 17 2019

Mylan Launches Advair Generic Wixela At 70% Discount To GSK's Branded Drug List Price

Feb 13 2019

Related Companies

Viatris Inc.

GSK plc

Eli Lilly and Company

Indivior plc

Talphera, Inc.

Johnson & Johnson

Novo Nordisk A/S

Sanofi

Additional Topics

United States Pricing Debate FDA Generic Drugs Policy Regulation BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window